October 2025 UPMC for You and UPMC Community HealthChoices formulary update

Oct. 2025Pharmacy Updates

Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.

There are covered alternatives that may be an option for your patients, depending on their health needs.

Tretinoin cream is a covered alternative for Retin-A (cream, gel).

Covered alternatives for Xifaxan include loperamide capsule, dicyclomine (10 mg capsule, 20 mg tablet), lactulose solution, and azithromycin. Coverage is available for Xifaxan 200 mg tablet for a diagnosis of hepatic encephalopathy only and a prior authorization is required. The dose and duration of therapy for Xifaxan 200 mg tablet must be consistent with nationally recognized compendia or peer-reviewed literature.

Xifaxan coverage update

Coverage of Xifaxan tablet, including both the 200 mg and 550 mg strengths, is no longer available under UPMC for You and UPMC Community HealthChoices.

The manufacturer of Xifaxan may provide the drug to Medicaid patients at no cost through its patient assistance program. The program application is available by phone at 1-833-862-8727 or online at bauschhealthpap.com.


Recent Announcements

CME Webinar: The State of Telehealth in 2026

Please join us for a live, CME-accredited webinar on Tuesday, Jan. 27, from noon to 1 p.m. that will share updates on the state of telehealth for 2026.
Dec. 2025Education/Webinars

Formulary updates effective Jan. 1, 2026

Review upcoming policy and operational updates
Dec. 2025Pharmacy Updates

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.
Nov. 2025Pharmacy Updates